If the cells you would like to access are currently listed as unavailable or you are ordering from outside of Europe please get in touch via Contact@EBiSC.org.

BIONi010-C-18

BIONi010-C TBK1 KO

Gene-edited iPSC line

Not-for-profit fee: £1700 per vial
Stock not immediately available - enquire for details
A CLIP contains information about a cell line including any specific third party obligations relating to, for example, licensing obligations or the donor consent which affect the use of the cell line.

The EBiSC Access and Use Agreement must be completed along with an individual Cell Line Information Pack for each line. Complete the EAUA and send to Contact@EBiSC.org for countersignature. The EAUA must be fully signed before proceeding with your order.
To receive the Certificate of Analysis, please contact us.
A batch specific Certificate of Analysis will be available to download once you receive your EBiSC iPSC line.

General#

Cell Line

hPSCreg name BIONi010-C-18
Alternative name(s)
BIONi010-C TBK1 KO
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
BIONi010-C
(BIONi010-C, K3P53)
BIONi010-C-3
(BIONi010-C ApoE KO #KO30 P30)
BIONi010-C-25
(BIONi010-C heterozygous TREM2 KO)
BIONi010-C-17
(BIONi010-C TREM2 KO)
BIONi010-C-15
(BIONi010-C +dox inducible NGN2-GFP)
BIONi010-C-13
(BIONi010-C + NGN2 #I7-26)
BIONi010-C-2
(BIONi010-C ApoE E3/E3 #H8 P32)
BIONi010-C-6
(BIONi010-C ApoE E2/E2)
BIONi010-C-7
(BIONi010-C Trem2 R47H)
BIONi010-C-8
(BIONi010-C Trem2 T66M, #Y5-80)
BIONi010-C-9
(BIONi010-C CD33 KO)
BIONi010-C-70
(BIONi010-C with an APOE 2/2 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-71
(BIONi010-C with an APOE 3/3 genotype with an additional, homozygous christchurch mutation)
BIONi010-C-4
(BIONi010-C ApoE E4/E4 #B44 P27)
BIONi010-C-5
(BIONi010-C CD33 E2del #N14 P26)
BIONi010-C-10
(HNF1AP291fsinsC +/- 54-5)
BIONi010-C-11
(HNF1AP291fsinsC -/- 66-1)
BIONi010-C-12
(HNF4ApR309C -/- 2-4)
BIONi010-C-52
(BIONi010-C with an APOE 2/2 genotype (with two functional alleles in contrast to BIONi010-C-6))
BIONi010-C-53
(BIONi010-C with an APOE 3/3 genotype (with two functional alleles in contrast to BIONi010-C-2))
BIONi010-C-55
(BIONi010-C TNNI3-mCherry/TNNI1-EGFP dual reporter cl. 74)
BIONi010-C-24
(BIONi010-C Dox a-syn)
BIONi010-C-51
(BIONi010-C TNNI3-mCherry reporter)
BIONi010-C-19
(BIONi010-C IKBKE KO)
BIONi010-A
(K1P53)
BIONi010-B
(K2P53, BIONi010-B)
Notes No larger chromosomal aberrations to be reported. Chr22: 1,4Mbp duplication in q11.23

Provider

Depositor Bioneer (BION)
Owner Bioneer (BION)
Distributors
EBiSC
Derivation country Denmark

External Databases

hPSCreg BIONi010-C-18
BioSamples SAMEA104491010
Cellosaurus CVCL_RM89
Wikidata Q54796763

General Information

This EBiSC line can be used for:
Yes
Research use: allowed
Clinical use: no
Commercial use: no
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Black or African-American

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA3105780

hIPSC Derivation#

General

The source cell information can be found in the parental cell line BIONi010-C.

Reprogramming method

Vector type Non-integrating
Vector Episomal

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions#

The following are the depositor culture conditions, they do not refer to any specific batch.
Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 20 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Morphology pictures
TREM2 KO cl. 24-54 D1 thaw after banking.tif
Morphology 1 day after thawing
Method documentation
qPCR BIONi010-C-18.tif
qPCR analysis of undifferentiated cells
06-Sep-2017-Layout.tiff
Flow cytometry analysis of undifferentiated cells
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Morphology
BIONi10-C18 endo d5 10x.tiff
Morphology of in vitro diff to endoderm
Protocol or reference
BIONi10-C18 endo d5.tiff
Flow Cytometry of in vitro differentiation to endoderm
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Morphology
BIONi10-C18 meso d5 10x.tiff
Morphology of in vitro diff to mesoderm
Protocol or reference
BIONi10-C18 meso d5.tiff
Flow Cytometry of in vitro differentiation to mesoderm
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Morphology
BIONi10-C18 ecto d5 10x.tiff
Morphology of in vitro diff to ectoderm
Protocol or reference
BIONi10-C18 ecto d5.tiff
Flow Cytometry of in vitro differentiation to ectoderm

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY
Passage number: 35
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification#

Disease/phenotype related modifications
Inflammatory diseases and cancer
Synonyms
  • inflammatory disorder
  • inflammation of anatomical structure
  • inflammatory disease
  • anatomical structure inflammation
show more synonyms
Genetic modifications
TBK1 (target)
Gene knock-out
12q14.2
KO of exon 2 of TBK1 (NM_013254)
CRISPR-associated (CRISPR/Cas) System
TBK1 KO BIONI010-C-18.pdf
Sequence and confirmation of single cell clone of BIONi010-C-18